MCID: RTN020
MIFTS: 48

Retinal Vascular Disease malady

Categories: Cardiovascular diseases, Eye diseases

Aliases & Classifications for Retinal Vascular Disease

Aliases & Descriptions for Retinal Vascular Disease:

Name: Retinal Vascular Disease 12 14
Retinal Vascular 52 69
Retina Circulation Disorder 12
Retinal Vascular Disorder 69

Classifications:



External Ids:

Disease Ontology 12 DOID:2462
NCIt 47 C35170
SNOMED-CT 64 57534004
UMLS 69 C0154833

Summaries for Retinal Vascular Disease

MalaCards based summary : Retinal Vascular Disease, also known as retinal vascular, is related to retinal vascular occlusion and exudative vitreoretinopathy, and has symptoms including chest pain An important gene associated with Retinal Vascular Disease is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Glioma and mTOR signaling pathway (KEGG). The drugs Dexamethasone and Mannitol have been mentioned in the context of this disorder. Affiliated tissues include retina and eye, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Retinal Vascular Disease

Diseases related to Retinal Vascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 86)
id Related Disease Score Top Affiliating Genes
1 retinal vascular occlusion 12.3
2 exudative vitreoretinopathy 10.7
3 vascular disease 10.4
4 retinitis 10.4
5 congenital toxoplasmosis 10.3 AKR1B1 SERPINF1 VEGFA
6 angular blepharoconjunctivitis 10.3 MTHFR SERPINF1 VEGFA
7 hand, foot and mouth disease 10.3 KDR PLG VEGFA
8 benign familial neonatal epilepsy 10.3 KDR SERPINF1 VEGFA
9 scar contracture 10.3 MTHFR SERPINF1 VEGFA
10 upper respiratory tract disease 10.3 CTGF PLG VEGFA
11 breast osteosarcoma 10.3 FZD4 NDP TSPAN12
12 phlegmonous dacryocystitis 10.3 ICAM1 KDR VEGFA
13 multilocular clear cell renal cell carcinoma 10.3 ICAM1 SERPINF1 VEGFA
14 capillary hemangioma 10.3 ALB MTHFR VEGFA
15 pancreas adenocarcinoma 10.3 MTHFR PLG VEGFA
16 pyriform sinus cancer 10.3 ICAM1 SERPINF1 VEGFA
17 cornea plana 10.3 FZD4 NDP TSPAN12
18 spinocerebellar ataxia 25 10.2 ALB KDR VEGFA
19 alcoholic gastritis 10.2 ALB MTHFR PLG
20 van buchem disease, type 2 10.2 FZD4 LRP5 NDP
21 neuropathy, hereditary sensory, type ib 10.2 KDR MTHFR VEGFA
22 kidney osteogenic sarcoma 10.2 FLT1 KDR VEGFA
23 neuropathy with hearing impairment 10.2 FLT1 KDR VEGFA
24 thyroid angiosarcoma 10.2 HBA1 VEGFA
25 astigmatism 10.2 FZD4 LRP5 NDP
26 fissured tongue 10.2 AKR1B1 ALB INS
27 vesiculobullous skin disease 10.2 HBA1 KDR VEGFA
28 intracranial hypotension 10.2 HBA1 KDR VEGFA
29 factitious disorder 10.2 HBA1 KDR VEGFA
30 dilated cardiomyopathy 10.2 AKR1B1 INS VEGFA
31 neurilemmoma of the pleura 10.2 HBA1 KDR VEGFA
32 malignant neoplasm of acoustic nerve 10.2 CTGF ICAM1 VEGFA
33 agammaglobulinemia 6 10.2 AKR1B1 ALB CTGF INS
34 vulvitis 10.2 FLT1 KDR VEGFA
35 human granulocytic anaplasmosis 10.2 FLT1 KDR VEGFA
36 breast fibroadenoma 10.2 HBA2 INS VEGFA
37 nystagmus 5, congenital, x-linked 10.2 FZD4 LRP5 NDP TSPAN12
38 biemond syndrome ii 10.1 FZD4 KDR NDP TSPAN12 VEGFA
39 brucella canis brucellosis 10.1 HBA2 INS VEGFA
40 obstructive jaundice 10.1 ALB FLT1 MTHFR VEGFA
41 laryngeal adenoid cystic carcinoma 10.1 FLT1 HBA1 VEGFA
42 anthrax disease 10.1 HBA1 PLG
43 welander distal myopathy 10.1 FLT1 MTHFR VEGFA
44 thymus adenosquamous carcinoma 10.1 FLT1 KDR SERPINF1 VEGFA
45 hypersensitivity pneumonitis, familial 10.1 HBA1 HBA2
46 ovarian disease 10.1 FLT1 KDR OCLN VEGFA
47 intracranial cysts 10.1 MTHFR VEGFA
48 pyrimidine metabolic disorder 10.1 ALB ICAM1 INS MTHFR VEGFA
49 ichthyosis, congenital, autosomal recessive 8 10.1 HBA1 HBA2
50 alzheimer's disease 11 10.1 HBA1 HBA2 MTHFR

Graphical network of the top 20 diseases related to Retinal Vascular Disease:



Diseases related to Retinal Vascular Disease

Symptoms & Phenotypes for Retinal Vascular Disease

UMLS symptoms related to Retinal Vascular Disease:


chest pain

MGI Mouse Phenotypes related to Retinal Vascular Disease:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.29 TSPAN12 VEGFA CTGF FLT1 FZD4 ICAM1
2 homeostasis/metabolism MP:0005376 10.25 VEGFA AKR1B1 ALB CTGF FLT1 FZD4
3 growth/size/body region MP:0005378 10.23 AKR1B1 CTGF FLT1 FZD4 ICAM1 INS
4 mortality/aging MP:0010768 10.18 INS KDR LRP5 AKR1B1 ALB CTGF
5 digestive/alimentary MP:0005381 10.15 ALB CTGF FZD4 ICAM1 INS OCLN
6 endocrine/exocrine gland MP:0005379 10.13 ALB FZD4 ICAM1 INS LRP5 OCLN
7 nervous system MP:0003631 10.07 AIPL1 FLT1 FZD4 ICAM1 INS KDR
8 integument MP:0010771 10.01 CTGF FZD4 ICAM1 INS KDR MTHFR
9 muscle MP:0005369 9.92 ALB FLT1 FZD4 ICAM1 INS KDR
10 reproductive system MP:0005389 9.85 PLG SERPINF1 VEGFA MTHFR NDP OCLN
11 skeleton MP:0005390 9.65 AKR1B1 CTGF INS KDR LRP5 MTHFR
12 vision/eye MP:0005391 9.5 AIPL1 AKR1B1 CTGF FLT1 FZD4 ICAM1

Drugs & Therapeutics for Retinal Vascular Disease

Drugs for Retinal Vascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 505)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
2
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
3
Fenofibrate Approved Phase 4,Phase 3 49562-28-9 3339
4
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
5
Zinc Approved Phase 4,Phase 3,Phase 2,Early Phase 1 7440-66-6 32051 23994
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
7
Acarbose Approved, Investigational Phase 4,Early Phase 1 56180-94-0 441184
8
Glatiramer Acetate Approved, Investigational Phase 4 147245-92-9 3081884
9
Dorzolamide Approved Phase 4,Phase 2,Phase 3 120279-96-1 3154 5284549
10
Verteporfin Approved, Investigational Phase 4,Phase 3,Phase 2 129497-78-5
11
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 124-94-7 31307
12
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
13
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 347396-82-1 459903
14
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
15
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
16
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
17
Verapamil Approved Phase 4 52-53-9 2520
18
Dipyridamole Approved Phase 4 58-32-2 3108
19
Metformin Approved Phase 4,Early Phase 1 657-24-9 14219 4091
20
Trandolapril Approved Phase 4 87679-37-6 5484727
21
Valsartan Approved, Investigational Phase 4,Phase 3 137862-53-4 60846
22
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
23
Copper Approved Phase 4,Phase 2 15158-11-9, 7440-50-8 27099
24
Timolol Approved Phase 4,Phase 2,Phase 3 26839-75-8 33624 5478
25
Ephedrine Approved Phase 4,Phase 2,Phase 3,Phase 1 299-42-3 9294
26
Brinzolamide Approved Phase 4 138890-62-7 68844
27
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
28
Liraglutide Approved Phase 4 204656-20-2
29
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
30
Pseudoephedrine Approved Phase 4,Phase 2,Phase 3,Phase 1 90-82-4 7028
31
Bimatoprost Approved, Investigational Phase 4,Phase 3 155206-00-1 5311027
32
Empagliflozin Approved Phase 4,Phase 3 864070-44-0
33
Insulin Glargine Approved Phase 4,Early Phase 1 160337-95-1
34
Temazepam Approved Phase 4,Phase 3,Phase 2,Phase 1 846-50-4 5391
35
Travoprost Approved Phase 4 157283-68-6 5282226
36
Dipivefrin Approved Phase 4 52365-63-6 3105
37
Glimepiride Approved Phase 4 93479-97-1 3476
38
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
39
Pyridoxine Approved, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
40
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 11103-57-4, 68-26-8 445354
41
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3 58-05-9 54575, 6560146 143
42
Glucosamine Approved, Nutraceutical Phase 4,Phase 1,Phase 2 3416-24-8 439213
43
Pyridoxal Approved, Nutraceutical Phase 4 66-72-8 1050
44
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59-30-3 6037
45
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
46
Choline Approved, Nutraceutical Phase 4 62-49-7 305
47
Vitamin C Approved, Nutraceutical Phase 4,Phase 2 50-81-7 5785 54670067
48
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-02-9 14985
49
Maleic acid Experimental Phase 4 110-16-7 444266
50 triamcinolone acetonide Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1072)
id Name Status NCT ID Phase
1 Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial) Unknown status NCT02092532 Phase 4
2 Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy Unknown status NCT01857544 Phase 4
3 Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation Unknown status NCT00677664 Phase 4
4 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4
5 Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED) Unknown status NCT01486771 Phase 4
6 Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO Unknown status NCT00566761 Phase 4
7 Changes in Macular Thickness After Patterns Scan Laser Unknown status NCT00563628 Phase 4
8 PASCAL Laser Versus ETDRS Laser Associated With Intravitreal Ranibizumab (IVR) Versus Only IVR for Proliferative Diabetic Retinopathy Unknown status NCT02005432 Phase 4
9 IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids Unknown status NCT00744666 Phase 4
10 Ranibizumab in Diabetic Vitrectomy Unknown status NCT01306981 Phase 4
11 The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease Unknown status NCT01306955 Phase 4
12 Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment Unknown status NCT00563043 Phase 4
13 Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy Unknown status NCT01382498 Phase 4
14 The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques Unknown status NCT01773512 Phase 4
15 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4
16 Effects of Fenofibrate on Endothelial Progenitor Cells in Diabetes Unknown status NCT01927315 Phase 4
17 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
18 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4
19 Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage Unknown status NCT01824043 Phase 4
20 Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor Unknown status NCT01896284 Phase 4
21 Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study Completed NCT01486238 Phase 4
22 Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy Completed NCT00674323 Phase 4
23 Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation Completed NCT01871376 Phase 4
24 PDT Study for Exudative AMD With PCV Completed NCT00331435 Phase 4
25 Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Completed NCT01950741 Phase 4
26 Visual Outcome in Patients With Symptomatic Macular PCV Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy. Completed NCT01846273 Phase 4
27 Effect of Antioxidants on Ocular Blood Flow, Endothelial Function, and Cytokine Levels in LPS Induced Inflammatory Model in Humans. Completed NCT00431691 Phase 4
28 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Completed NCT00682240 Phase 4
29 Ranibizumab in Patients With Branch Retinal Vein Occlusion Completed NCT01027481 Phase 4
30 Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Completed NCT01710839 Phase 4
31 A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT) Completed NCT00235014 Phase 4
32 Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion Completed NCT00406107 Phase 4
33 NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions Completed NCT01870427 Phase 4
34 Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion Completed NCT01448018 Phase 4
35 Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion Completed NCT01085734 Phase 4
36 Influence of Prostaglandins on Ocular Blood Flow in Glaucoma Patients Completed NCT00308945 Phase 4
37 Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion Completed NCT01427751 Phase 4
38 A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion Completed NCT01903720 Phase 4
39 Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO Completed NCT01580020 Phase 4
40 A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion Completed NCT01277302 Phase 4
41 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
42 Dexamethasone-implant for the Treatment of RVO Completed NCT01767545 Phase 4
43 Effect of the Adjunctive IVB Before PRP Completed NCT01504724 Phase 4
44 Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients. Completed NCT01997489 Phase 4
45 Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema. Completed NCT02140411 Phase 4
46 Unilateral Bevacizumab for Bilateral Diabetic Macular Edema Completed NCT00496405 Phase 4
47 Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation Completed NCT01223612 Phase 4
48 Neural Conduction Along the Visual Pathways After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases Completed NCT00404729 Phase 4
49 Vascular Endothelial Growth Factor in Stage V ROP Completed NCT00500396 Phase 4
50 Topical Application of Latanoprost in Diabetic Retinopathy Completed NCT01225653 Phase 4

Search NIH Clinical Center for Retinal Vascular Disease

Genetic Tests for Retinal Vascular Disease

Anatomical Context for Retinal Vascular Disease

MalaCards organs/tissues related to Retinal Vascular Disease:

39
Retina, Eye

Publications for Retinal Vascular Disease

Articles related to Retinal Vascular Disease:

(show top 50) (show all 61)
id Title Authors Year
1
Adult lead exposure increases blood-retinal permeability: A risk factor for retinal vascular disease. ( 27663850 )
2016
2
Cell Therapy Applications for Retinal Vascular Diseases: Diabetic Retinopathy and Retinal Vein Occlusion. ( 27116667 )
2016
3
Nanoengineering of therapeutics for retinal vascular disease. ( 26022642 )
2015
4
Systemic atheromatosis influence on retinal vascular disease. ( 25729610 )
2014
5
Changes in the foveal microstructure after intravitreal bevacizumab application in patients with retinal vascular disease. ( 23355773 )
2013
6
Regional morphology and pathophysiology of retinal vascular disease. ( 23892140 )
2013
7
[Cytokine determination from vitreous samples in retinal vascular diseases]. ( 23224211 )
2013
8
Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease? ( 22250209 )
2012
9
The role of glia in retinal vascular disease. ( 22519424 )
2012
10
Retinal vascular disease and the pathogenesis of facioscapulohumeral muscular dystrophy. A signalling message from Wnt? ( 21377364 )
2011
11
The multifactorial nature of retinal vascular disease. ( 20714177 )
2010
12
[Aging and retinal vascular diseases]. ( 17402563 )
2007
13
Molecular targets for retinal vascular diseases. ( 17133346 )
2007
14
Newly recognized serous macular detachment in retinal vascular disease. ( 16770254 )
2006
15
Retinal vascular disease in hypertension. Risk factor modification optimizes vision outcomes. ( 16001767 )
2005
16
Methylenetetrahydrofolate reductase gene polymorphism, hyperhomocysteinemia and occlusive retinal vascular disease in type 2 diabetic and non-diabetic subjects. ( 12356186 )
2002
17
Plasma total homocysteine and retinal vascular disease. ( 11040905 )
2000
18
Association of antiphospholipid antibodies with retinal vascular disease in systemic lupus erythematosus. ( 10342390 )
1999
19
Ambulatory blood pressure monitoring in cerebrovascular and retinal vascular disease. ( 17895021 )
1997
20
Ambulatory blood pressure monitoring in cerebrovascular and retinal vascular disease. ( 17895027 )
1997
21
Antiphospholipid antibodies and retinal vascular disease. ( 8869905 )
1996
22
On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy. ( 23573590 )
1995
23
On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy. ( 7739630 )
1995
24
Retinal vascular disease in ulcerative colitis. ( 8085600 )
1994
25
Arnall Patz Medal for Excellence in Retinal Vascular Disease. Matthew D. Davis, MD. ( 1439249 )
1992
26
Cerebral ischemic events associated with endocarditis, retinal vascular disease, and lupus anticoagulant. ( 1900660 )
1991
27
Semiconductor diode laser photocoagulation in retinal vascular disease. ( 2255529 )
1990
28
The patency of the retinal vasculature to erythrocytes in retinal vascular disease. ( 2318585 )
1990
29
Crohn's disease and retinal vascular disease. ( 2220968 )
1990
30
Antiphospholipid antibodies associated with retinal vascular disease. ( 2133045 )
1990
31
Initial clinical experience using a diode laser in the treatment of retinal vascular disease. ( 2630328 )
1989
32
Occlusive retinal vascular disease in two patients. ( 2788911 )
1989
33
The tunable dye laser in the management of retinal vascular disease. ( 3229908 )
1988
34
Antiphospholipid antibodies associated with retinal vascular disease. ( 3124231 )
1987
35
The eyes of Woodrow Wilson. Retinal vascular disease and George de Schweinitz. ( 3887267 )
1985
36
Occlusive retinal vascular disease in systemic lupus erythematosus. ( 6084063 )
1984
37
Treatment of retinal vascular disease using photocoagulation and cryotherapy. ( 6676223 )
1983
38
Digital subtraction angiography in the diagnosis of retinal vascular disease. ( 6195923 )
1983
39
Photocoagulation in retinal vascular disease. ( 281780 )
1977
40
Retinal vascular disease: introduction and phenomenology. ( 888253 )
1977
41
Selected molecular weight dextrans for in vivo permeability studies of rat retinal vascular disease. ( 872904 )
1977
42
Clinical understanding in the management of retinal vascular disease. ( 1070871 )
1976
43
Occlusive retinal vascular disease and deafness. ( 949074 )
1976
44
Symposium on retinal vascular disease. Conclusion. ( 1070875 )
1976
45
Retinal vascular disease. ( 4415614 )
1974
46
Evolution of hypertensive retinal vascular disease: correlation between clinical and postmortem observations. ( 4748590 )
1973
47
Photocoagulation of retinal vascular disease. ( 4507180 )
1972
48
Platelet aggregation studies in ischaemic retinal vascular disease. ( 5291525 )
1971
49
Treatment of retinal vascular disease with argon laser slit lamp photocoagulation. ( 5499912 )
1970
50
A fluorescein angiographic study of macular dysfunction secondary to retinal vascular disease. V. Retinal telangiectasis. ( 5684308 )
1968

Variations for Retinal Vascular Disease

Expression for Retinal Vascular Disease

Search GEO for disease gene expression data for Retinal Vascular Disease.

Pathways for Retinal Vascular Disease

Pathways related to Retinal Vascular Disease according to GeneCards Suite gene sharing:

(show all 15)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.85 FLT1 FZD4 INS KDR LRP5 VEGFA
2
Show member pathways
12.23 FLT1 FZD4 INS KDR LRP5
3 11.83 ALB INS KDR VEGFA
4 11.72 FLT1 INS VEGFA
5
Show member pathways
11.68 FLT1 KDR VEGFA
6 11.65 FLT1 ICAM1 VEGFA
7
Show member pathways
11.43 ALB HBA1 ICAM1 INS MTHFR PLG
8 11.36 KDR PLG VEGFA
9 11.34 HBA1 HBA2 ICAM1
10 11.31 CTGF ICAM1 PLG
11
Show member pathways
11.23 INS KDR VEGFA
12 11.04 HBA1 HBA2 ICAM1
13 10.96 FLT1 KDR VEGFA
14 10.71 FLT1 KDR VEGFA
15
Show member pathways
10.34 FLT1 KDR VEGFA

GO Terms for Retinal Vascular Disease

Cellular components related to Retinal Vascular Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.8 FZD4 ICAM1 NDP PLG VEGFA
2 extracellular region GO:0005576 9.7 ALB CTGF FLT1 HBA1 HBA2 INS
3 blood microparticle GO:0072562 9.56 ALB HBA1 HBA2 PLG
4 platelet alpha granule lumen GO:0031093 9.5 ALB PLG VEGFA
5 endocytic vesicle lumen GO:0071682 9.43 HBA1 HBA2
6 extracellular space GO:0005615 9.4 AKR1B1 ALB CTGF FLT1 HBA1 HBA2
7 hemoglobin complex GO:0005833 9.37 HBA1 HBA2
8 haptoglobin-hemoglobin complex GO:0031838 9.16 HBA1 HBA2

Biological processes related to Retinal Vascular Disease according to GeneCards Suite gene sharing:

(show all 25)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.99 AIPL1 AKR1B1 ALB KDR VEGFA
2 positive regulation of cell migration GO:0030335 9.8 FLT1 INS KDR VEGFA
3 positive regulation of cell proliferation GO:0008284 9.8 CTGF FLT1 INS KDR LRP5 VEGFA
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.77 ICAM1 INS VEGFA
5 positive regulation of MAPK cascade GO:0043410 9.76 FLT1 INS KDR
6 canonical Wnt signaling pathway GO:0060070 9.74 FZD4 LRP5 NDP
7 cellular oxidant detoxification GO:0098869 9.73 ALB HBA1 HBA2
8 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.72 FLT1 KDR VEGFA
9 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.71 FLT1 INS KDR
10 vasculogenesis GO:0001570 9.7 FZD4 KDR VEGFA
11 angiogenesis GO:0001525 9.65 CTGF FLT1 KDR TSPAN12 VEGFA
12 cell migration involved in sprouting angiogenesis GO:0002042 9.62 KDR VEGFA
13 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.62 FLT1 VEGFA
14 oxygen transport GO:0015671 9.61 HBA1 HBA2
15 negative regulation of cell-substrate adhesion GO:0010812 9.61 FZD4 PLG
16 positive regulation of cell death GO:0010942 9.61 CTGF HBA1 HBA2
17 positive regulation of positive chemotaxis GO:0050927 9.58 KDR VEGFA
18 response to amino acid GO:0043200 9.54 CTGF ICAM1 MTHFR
19 vascular endothelial growth factor signaling pathway GO:0038084 9.51 FLT1 KDR
20 regulation of cGMP metabolic process GO:0030823 9.48 AIPL1 VEGFA
21 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.46 KDR VEGFA
22 retinal blood vessel morphogenesis GO:0061304 9.4 FZD4 LRP5
23 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.33 FLT1 KDR VEGFA
24 retina vasculature morphogenesis in camera-type eye GO:0061299 9.13 FZD4 LRP5 NDP
25 extracellular matrix-cell signaling GO:0035426 8.8 FZD4 LRP5 NDP

Molecular functions related to Retinal Vascular Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 AIPL1 ALB CTGF FLT1 FZD4 HBA1
2 oxygen binding GO:0019825 9.43 ALB HBA1 HBA2
3 oxygen transporter activity GO:0005344 9.37 HBA1 HBA2
4 vascular endothelial growth factor-activated receptor activity GO:0005021 9.32 FLT1 KDR
5 haptoglobin binding GO:0031720 9.16 HBA1 HBA2
6 Wnt-activated receptor activity GO:0042813 8.8 FZD4 LRP5 TSPAN12

Sources for Retinal Vascular Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....